Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

Media Info

Our media releases, presentations for the media and useful links

Contact

Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich
T: +41 44 455 56 78
E-mail

2019

May 7, 2019

Swiss biotechnology: Investments at record level

The Swiss biotech industry continues to be buoyant and once again managed to increase its sales, exports and research investments in 2018. As a result, it is laying the foundations for further growth and forward-looking development. Capital investment in listed biotech companies saw an especially striking increase: Polyphor boasted one of Europe’s most successful flotations in recent years.
 
May 7, 2019

Awards for outstanding achievements

This year, the Swiss Biotech Association again nominated organizations and people for the “Swiss Biotech Success Stories Awards” in recognition of outstanding achievements:  Nobel Prize winner Prof. Dr. Werner Arber, Actelion, Debiopharm, Helsinn, and biotech startup supporters Venture, Venturelab and Venture Kick.

More on the Swiss Biotech Success Stories

Media releases & presentations 2019

2018

May 4, 2018

The Swiss Biotech Association honors major industry achievements with Swiss Biotech Success Stories

On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments. Swiss Biotech Success Stories will grow over time to encompass all of the industry’s different facets. An independent jury of experts annually selects the laureates. The first recognitions go to Biogen, Glycart, Okairos, Selexis and Vifor Fresenius Medical Care Renal Pharma for their remarkable achievements and sustainable contributions to Switzerland and its biotech industry. Founders, scientists, investors and business partners celebrated the first laureates yesterday evening at this year’s Swiss Biotech Day.

More on the Swiss Biotech Success Stories

May 3, 2018​

The unbridled success of the Swiss Biotech industry continues apace

The Swiss biotech industry has reached record figures for 2017 in financing, infrastructure investment, and exports. This shows that confidence in its ability to create value and innovate remains unshaken. The most prominent example is the acquisition of Actelion by Johnson & Johnson, which, at almost USD 30 billion, was the largest stock exchange transaction worldwide within the life sciences industry over the past year.

Find the full the media release in 3 languages, as well as the Swiss Biotech Report media presentation below.

More on the Swiss Biotech Report

Media releases & presentations 2018